Quince Therapeutics (QNCX) Price & Analysis

Compare

918 Followers

QNCX Stock Chart & Stats

$3.65

-$0.07(-3.61%)

At close: Jan 08 4:00 PM EST

$3.65

-$0.07(-3.61%)

Day’s Range― - ―

52-Week Range$0.72 - $3.73

Previous CloseN/A

Volume30.57K

Average Volume (3M)552.37K

Market Cap

$203.24M

Enterprise Value$79.65M

Total Cash (Recent Filing)$26.29M

Total Debt (Recent Filing)$17.99M

Price to Earnings (P/E)―

Beta0.12

Next Earnings

Mar 03, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding55,681,490

10 Day Avg. Volume936,444

30 Day Avg. Volume552,366

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.68

Price to Sales (P/S)0.00

P/FCF Ratio-2.52

Enterprise Value/Market Cap0.39

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-669.29

Enterprise Value/Ebitda-1.46

Forecast

1Y Price Target

$8.00

Price Target Upside119.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.07

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe P3 NEAT study of encapsulated dexamethasone sodium phosphate (eDSP) in Ataxia-Telangectasia is a key event for QNCX shares, and is expected to produce top-line data soon.

Regulatory ProspectsIf successful, an NDA is expected to be filed, and the probability of a successful outcome for NEAT favors Quince based on prior data.

Technology And InnovationEDSP leverages Quince's AIDE technology platform, offering therapeutic benefits for ataxia-telangiectasia patients with less drug and safety issues compared to traditional methods.

Bears Say

Quince Therapeutics News

Quince Therapeutics reports Q3 EPS (25c), consensus (22c)

Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report...

19d ago

QNCX

Quince Therapeutics announces positive iDSMB review for eDSP in Phase 3 study

Quince Therapeutics (QNCX) “announced the positive outcome of its pre-planned safety analysis conducted by an independent data and...

21d ago

QNCX

Promising Outlook for Quince Therapeutics: Phase 3 Study and Innovative Platform Drive Buy Recommendation

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics and keeping the price target...

16d ago

QNCX

Quince Therapeutics Reports Q3 2025 Financial Results

Quince Therapeutics ( ($QNCX) ) has released its Q3 earnings. Here is a breakdown of the information Quince...

19d ago

QNCX

QNCX Upcoming Earnings Report: What to Expect?

Quince Therapeutics (QNCX) is scheduled to report 3rd quarter earnings on 11/13/2025. Regarding Q3 estimates, Wall Street analysts...

20d ago

QNCX

Quince Therapeutics Updates on NALL Study Efficacy

The latest update is out from Quince Therapeutics ( ($QNCX) ). Quince Therapeutics, Inc. hosted a Virtual Investor...

1M ago

QNCX

Quince Therapeutics presents data from patient-reported walking capacity at CNS

Quince Therapeutics (QNCX) announced the poster presentation of patient-reported walking capacity in children with Ataxia-Telangiectasia at the 54th...

2M ago

QNCX

Quince Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial and Strong Financial Position

Quince Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

2M ago

QNCX

Quince Therapeutics Amends Credit Facility Agreement

Quince Therapeutics ( ($QNCX) ) has provided an update. On September 25, 2025, Quince Therapeutics amended its unsecured...

2M ago

QNCX

Quince Therapeutics price target lowered to $8 from $9 at Citizens JMP

Citizens JMP lowered the firm’s price target on Quince Therapeutics (QNCX) to $8 from $9 and keeps an...

4M ago

QNCX

Quince Therapeutics Reports Q2 2025 Financial Results

Quince Therapeutics ( ($QNCX) ) has released its Q2 earnings. Here is a breakdown of the information Quince...

4M ago

QNCX

Quince Therapeutics reports Q2 EPS (34c), consensus (23c)

Reported cash, cash equivalents, and short-term investments of $34.7 million for the second quarter ended June 30, 2025....

4M ago

QNCX

QNCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Quince Therapeutics (QNCX) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street analysts...

4M ago

QNCX

Quince Therapeutics initiated with an Outperform at Citizens JMP

Citizens JMP initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $9 price target The firm...

4M ago

QNCX

QNCX FAQ

What was Quince Therapeutics’s price range in the past 12 months?

Quince Therapeutics lowest stock price was $0.72 and its highest was $3.73 in the past 12 months.

What is Quince Therapeutics’s market cap?

Quince Therapeutics’s market cap is $203.24M.

When is Quince Therapeutics’s upcoming earnings report date?

Quince Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 92 days.

How were Quince Therapeutics’s earnings last quarter?

Quince Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$0.035.

Is Quince Therapeutics overvalued?

According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quince Therapeutics pay dividends?

Quince Therapeutics does not currently pay dividends.

What is Quince Therapeutics’s EPS estimate?

Quince Therapeutics’s EPS estimate is -0.18.

How many shares outstanding does Quince Therapeutics have?

Quince Therapeutics has 55,681,490 shares outstanding.

What happened to Quince Therapeutics’s price movement after its last earnings report?

Quince Therapeutics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went down -1.754%.

Which hedge fund is a major shareholder of Quince Therapeutics?

Currently, no hedge funds are holding shares in QNCX

Quince Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-247.78%

Trailing 12-Months

Asset Growth

-13.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Quince Therapeutics

Quince Therapeutics (QNCX) is a biopharmaceutical company focused on developing innovative treatments for patients suffering from chronic and debilitating diseases. Operating within the healthcare and biotechnology sectors, Quince Therapeutics leverages advanced scientific research and cutting-edge technology to design and develop therapeutic solutions aimed at addressing unmet medical needs. The company's core products include a pipeline of drug candidates that target specific molecular pathways implicated in various diseases.

Quince Therapeutics (QNCX) Earnings & Revenues

Historic Earnings Reports

QNCX Stock 12 Month Forecast

Average Price Target

$8.00

▲(119.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.65,2.292307692307692,2.9346153846153844,3.5769230769230766,4.219230769230769,4.861538461538461,5.503846153846153,6.146153846153846,6.788461538461538,7.430769230769231,8.073076923076922,8.715384615384615,9.357692307692307,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.65,2.1384615384615384,2.626923076923077,3.115384615384615,3.6038461538461535,4.092307692307692,4.5807692307692305,5.069230769230769,5.5576923076923075,6.046153846153846,6.534615384615384,7.023076923076923,7.511538461538461,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.65,1.9846153846153844,2.319230769230769,2.6538461538461537,2.9884615384615385,3.323076923076923,3.6576923076923076,3.992307692307692,4.326923076923077,4.661538461538461,4.996153846153845,5.3307692307692305,5.665384615384616,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >